<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Montair LC - Scientific Portal</title>
    <style>
        :root {
            /* Red/Yellow Product Theme */
            --primary-color: #D92323; /* Strong Red */
            --secondary-color: #FFB300; /* Warm Yellow/Gold */
            --accent-color: #E65100; /* Deep Orange for accents */
            
            --text-color: #333;
            --text-on-dark: #ffffff;
            --bg-color: #f9f9f9; 
            --white: #ffffff;
            --grey: #eaeaea;
            --success: #28a745;
            --danger: #dc3545;
        }
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
            margin: 0;
            background-color: var(--bg-color);
            color: var(--text-color);
            line-height: 1.6;
        }
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
        }
        /* Header & Nav */
        header {
            background-color: var(--white);
            border-bottom: 2px solid var(--grey);
            padding: 20px 40px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        header h1 {
            color: var(--primary-color);
            font-size: 28px;
            margin: 0;
            font-weight: 700;
        }
        nav {
            display: flex;
            gap: 15px;
            flex-wrap: wrap;
        }
        nav a {
            text-decoration: none;
            color: var(--primary-color);
            font-weight: 600;
            padding: 8px 12px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }
        nav a:hover, nav a.active {
            background-color: var(--bg-color);
            color: var(--accent-color);
        }

        /* Hero Section */
        .hero {
            background: linear-gradient(to right, var(--primary-color), var(--secondary-color));
            color: var(--text-on-dark);
            padding: 50px 40px;
            text-align: center;
            border-radius: 12px;
            margin-top: 20px;
        }
        .hero h2 {
            font-size: 38px;
            margin: 0 0 10px 0;
        }
        .hero p {
            font-size: 20px;
            opacity: 0.9;
        }

        /* Section Styling */
        .section {
            background: var(--white);
            padding: 30px;
            margin-top: 25px;
            border-radius: 12px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.05);
        }
        .section h3 {
            font-size: 28px;
            color: var(--primary-color);
            border-bottom: 2px solid var(--secondary-color);
            padding-bottom: 10px;
            margin-top: 0;
        }

        /* Indication Grid Layout */
        .indication-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
            margin-top: 20px;
            align-items: flex-start;
        }
        .indication-grid .text-content {
            padding-right: 20px;
        }
        .indication-grid .data-card {
            background: var(--bg-color);
            border: 2px solid var(--secondary-color);
            border-radius: 10px;
            padding: 25px;
        }
        .data-card h4 {
            margin: 0 0 15px 0;
            color: var(--accent-color);
            font-size: 22px;
        }
        .data-card ul {
            padding-left: 20px;
            list-style-type: 'âœ“ ';
        }
        .data-card ul li {
            font-size: 16px;
            margin-bottom: 10px;
            padding-left: 10px;
        }
        
        /* Citable Links */
        a.citation-link {
            text-decoration: none;
            color: var(--accent-color);
            font-weight: 600;
        }
        a.citation-link:hover {
            text-decoration: underline;
        }

        /* NEW Gamification */
        .triage-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        .patient-card {
            border: 1px solid var(--grey);
            border-radius: 8px;
            padding: 20px;
            background: var(--bg-color);
            display: flex;
            flex-direction: column;
        }
        .patient-card h4 {
            margin: 0 0 15px 0;
            color: var(--primary-color);
            font-size: 20px;
        }
        .patient-card .scenario {
            font-size: 15px;
            font-style: italic;
            margin: 0 0 15px 0;
            flex-grow: 1; /* Makes cards equal height */
        }
        .patient-card .options-list {
            list-style: none;
            padding: 0;
            margin: 0;
        }
        .patient-card .options-list li {
            margin-bottom: 10px;
        }
        .patient-card input[type="radio"] {
            margin-right: 10px;
        }
        .patient-card label {
            font-size: 16px;
            cursor: pointer;
        }

        .check-btn {
            background-color: var(--accent-color);
            color: var(--text-on-dark);
            border: none;
            padding: 12px 20px;
            font-size: 16px;
            font-weight: 600;
            border-radius: 6px;
            cursor: pointer;
            margin-top: 20px;
            transition: background-color 0.2s;
        }
        .check-btn:hover {
            background-color: var(--primary-color);
        }
        #triage-rationale {
            display: none;
            margin-top: 20px;
            padding: 20px;
            border-radius: 8px;
            background: #fff8e1; /* Light yellow */
            border: 2px solid var(--secondary-color);
        }
        #triage-rationale h5 {
            color: var(--accent-color);
            margin: 0 0 10px 0;
            font-size: 18px;
        }
        
        /* Responsive Media Queries */
        @media (max-width: 900px) {
            .indication-grid {
                grid-template-columns: 1fr;
            }
        }
        @media (max-width: 768px) {
            header {
                flex-direction: column;
                align-items: flex-start;
                gap: 15px;
            }
            nav {
                width: 100%;
                justify-content: space-around;
            }
        }

    </style>
</head>
<body>

    <header>
        <h1>Montair LC</h1>
        <nav>
            <a href="#ar" class="active">Allergic Rhinitis</a>
            <a href="#asthma">Asthma</a>
            <a href="#overlap">AR-Asthma Overlap</a>
            <a href="#gamification">Case Studies</a>
        </nav>
    </header>

    <div class="container">

        <section class="hero">
            <h2>Comprehensive Control for Allergic Rhinitis & Asthma</h2>
            <p>A dual-blockade FDC targeting the key inflammatory pathways for upper and lower airway disease.</p>
        </section>

        <section class="section" id="ar">
            <h3>Indication 1: Allergic Rhinitis (AR)</h3>
            <div class="indication-grid">
                <div class="text-content">
                    <p>For AR patients, especially those with nasal congestion, monotherapy often falls short. The FDC provides a dual blockade to control the full spectrum of symptoms.</p>
                    <p><strong>Levocetirizine (H1-Blocker):</strong> Targets histamine, the primary driver of acute symptoms like sneezing, rhinorrhea, and pruritus.</p>
                    <p><strong>Montelukast (LTRA):</strong> Targets leukotrienes, the key mediators of late-phase inflammation responsible for persistent nasal congestion (<a class="citation-link" href="https://go.drugbank.com/drugs/DB00471" target="_blank">DrugBank</a>).</p>
                </div>
                <div class="data-card">
                    <h4>Clinical Proof: Superior Efficacy</h4>
                    <ul>
                        <li>A Phase III, randomized, double-blind trial found the Montelukast + Levocetirizine FDC showed a **statistically significant greater improvement** in daytime nasal symptom scores vs. monotherapy (<a class="citation-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343361/" target="_blank">Panchal S, et al. 2021</a>).</li>
                        <li>A 2024 meta-analysis confirmed the FDC provided significantly better outcomes for **nasal obstruction** (congestion) compared to monotherapy (<a class="citation-link" href="https://pubmed.ncbi.nlm.nih.gov/37666275/" target="_blank">Eur Ann Allergy Clin Immunol. 2024</a>).</li>
                        <li>In pediatric patients (6-14 yrs), the FDC was significantly more effective than montelukast alone at reducing **daytime nasal congestion (p=0.0341)** (<a class="citation-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904771/" target="_blank">Kim CK, et al. 2021</a>).</li>
                    </ul>
                </div>
            </div>
        </section>

        <section class="section" id="asthma">
            <h3>Indication 2: Asthma</h3>
            <div class="indication-grid">
                <div class="text-content">
                    <p>The **Montelukast** component directly addresses the underlying pathophysiology of asthma as a Leukotriene Receptor Antagonist (LTRA).</p>
                    <p>Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators that cause bronchoconstriction, airway edema, and mucus secretion. By blocking the CysLT1 receptor, Montelukast provides anti-inflammatory and bronchodilatory effects.</p>
                    <p>It is recommended in **GINA guidelines** as an adjunctive or alternative anti-inflammatory therapy for mild-to-moderate persistent asthma (<a class="citation-link" href="https://ginasthma.org/gina-reports/" target="_blank">GINA 2024</a>).</p>
                </div>
                <div class="data-card">
                    <h4>Clinical Proof: Symptom Control</h4>
                    <ul>
                        <li>In a study of adult patients with mild-to-moderate persistent asthma, 4 weeks of add-on Montelukast treatment demonstrated significant clinical improvements:</li>
                        <li>**83.3% improvement** in exercise tolerance</li>
                        <li>**80% improvement** in early morning wakening</li>
                        <li>(<a class="citation-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070216/" target="_blank">Al-Rubaish A, 2014</a>)</li>
                    </ul>
                </div>
            </div>
        </section>

        <section class="section" id="overlap">
            <h3>Indication 3: The AR-Asthma Overlap (Unified Airway)</h3>
            <div class="indication-grid">
                <div class="text-content">
                    <p>This is where the FDC provides its most significant advantage. Studies show that a high percentage of patients with asthma also suffer from AR. Both conditions are manifestations of a "Unified Airway Disease."</p>
                    <p>The **ARIA guidelines** explicitly recommend treating AR in asthmatic patients to improve asthma control (<a class="citation-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005182/" target="_blank">Bousquet J, et al. 2020</a>).</p>
                    <p>Montair LC is uniquely positioned to treat both the upper (AR) and lower (Asthma) airway inflammation simultaneously.</p>
                </div>
                <div class="data-card">
                    <h4>Clinical Proof: Managing Comorbidity</h4>
                    <ul>
                        <li>Leukotrienes are the common inflammatory pathway for *both* AR nasal congestion and asthmatic bronchoconstriction.</li>
                        <li>A retrospective study on patients with asthma and comorbid seasonal AR found that adding montelukast to their therapy **significantly improved long-term asthma control** and led to **substantial reductions in asthma-related resource use** (<a class="citation-link" href="https://pubmed.ncbi.nlm.nih.gov/30025514/" target="_blank">Price D, et al. 2018</a>).</li>
                    </ul>
                </div>
            </div>
        </section>

        <section class="section" id="gamification">
            <h3>Clinical Case Challenge</h3>
            <p>Based on the data, select the optimal therapeutic strategy for each patient.</p>
            
            <div class="triage-grid">
                
                <div class="patient-card">
                    <h4>Case 1: The INS Non-Compliant Patient</h4>
                    <p class="scenario">A 28-year-old female presents with seasonal AR (sneezing, itching, rhinorrhea). You prescribed an intranasal steroid (INS) last season, but she reports she "hates the feeling" and is non-compliant. She is currently using OTC loratadine with only partial relief.</p>
                    <ul class="options-list">
                        <li><label><input type="radio" name="patient-a" value="INS"> Re-educate on INS technique</label></li>
                        <li><label><input type="radio" name="patient-a" value="DECON"> Add oral decongestant</label></li>
                        <li><label><input type="radio" name="patient-a" value="FDC"> Switch to FDC (Montair LC)</label></li>
                        <li><label><input type="radio" name="patient-a" value="AH"> Switch to Levocetirizine Monotherapy</label></li>
                    </ul>
                </div>

                <div class="patient-card">
                    <h4>Case 2: The "Sinus" Patient</h4>
                    <p class="scenario">A 45-year-old male, non-smoker, with perennial nasal congestion and "sinus pressure." He also mentions a "mild, dry cough" he gets at night, which he attributes to "post-nasal drip." He has failed on levocetirizine monotherapy in the past, saying it "didn't touch the congestion."</p>
                    <ul class="options-list">
                        <li><label><input type="radio" name="patient-b" value="INS"> Prescribe INS Monotherapy</label></li>
                        <li><label><input type="radio" name="patient-b" value="FDC"> Prescribe FDC (Montair LC)</label></li>
                        <li><label><input type="radio" name="patient-b" value="DECON"> Add Decongestant to Antihistamine</label></li>
                        <li><label><input type="radio" name="patient-b" value="SPIRO"> Refer for Spirometry & Allergy Test</label></li>
                    </ul>
                </div>

                <div class="patient-card">
                    <h4>Case 3: The Partially Controlled Asthmatic</h4>
                    <p class="scenario">A 32-year-old with known mild persistent asthma and AR. She is *already* on a low-dose ICS (Budesonide) but still uses her SABA 3-4x/week. She reports her AR "acts up" frequently (congestion, itching), and this often "triggers her wheezing."</p>
                    <ul class="options-list">
                        <li><label><input type="radio" name="patient-c" value="ICS"> Double the ICS Dose</label></li>
                        <li><label><input type="radio" name="patient-c" value="LABA"> Switch to an ICS/LABA Combo</label></li>
                        <li><label><input type="radio" name="patient-c" value="FDC"> Add FDC (Montair LC) to her regimen</label></li>
                        <li><label><input type="radio" name="patient-c" c="AH"> Add Levocetirizine Monotherapy</label></li>
                    </ul>
                </div>

            </div>
            <button class="check-btn" onclick="checkTriage()">Check Case Decisions</button>
            <div id="triage-rationale"></div>
        </section>

    </div>

    <script>
        function getRadioValue(name) {
            const radio = document.querySelector(`input[name="${name}"]:checked`);
            return radio ? radio.value : 'none';
        }

        function checkTriage() {
            const answers = {
                'patient-a': getRadioValue('patient-a'),
                'patient-b': getRadioValue('patient-b'),
                'patient-c': getRadioValue('patient-c')
            };
            const key = {
                'patient-a': 'FDC',
                'patient-b': 'FDC',
                'patient-c': 'FDC'
            };
            let correctCount = 0;
            if (answers['patient-a'] === key['patient-a']) correctCount++;
            if (answers['patient-b'] === key['patient-b']) correctCount++;
            if (answers['patient-c'] === key['patient-c']) correctCount++;

            const rationaleDiv = document.getElementById('triage-rationale');
            let rationaleHTML = `<h3>Triage Rationale (${correctCount}/3 Correct)</h3>`;

            // Patient A Rationale
            rationaleHTML += `<h5>Case 1: The INS Non-Compliant Patient</h5>
            <p><strong>Your Choice: ${answers['patient-a']} | Correct: ${key['patient-a']}</strong><br>
            Rationale: While re-educating on INS is first-line, the patient is already non-compliant. The FDC (Montair LC) is the strongest *oral* option. Her partial relief from an antihistamine shows a histamine component, but her symptoms warrant a second mediator. The FDC provides comprehensive, single-pill oral compliance by blocking both histamine (Levocetirizine) and leukotrienes (Montelukast).</p>`;

            // Patient B Rationale
            rationaleHTML += `<h5>Case 2: The "Sinus" Patient</h5>
            <p><strong>Your Choice: ${answers['patient-b']} | Correct: ${key['patient-b']}</strong><br>
            Rationale: This is a classic "Unified Airway" presentation. His "sinus" congestion (leukotriene-driven) and "dry cough" (a sign of mild asthma) point away from simple AR. His failure on monotherapy confirms antihistamines alone are not enough. The FDC (Montair LC) is the ideal choice, as the Montelukast component targets *both* his leukotriene-driven congestion AND his underlying lower airway inflammation.</p>`;

            // Patient C Rationale
            rationaleHTML += `<h5>Case 3: The Partially Controlled Asthmatic</h5>
            <p><strong>Your Choice: ${answers['patient-c']} | Correct: ${key['patient-c']}</strong><br>
            Rationale: This patient's asthma is uncontrolled *because* her AR is uncontrolled. While increasing the ICS or adding a LABA are valid asthma strategies, they ignore the *trigger* (her AR). Adding the FDC (Montair LC) is the most logical step:
            1. The **Levocetirizine** controls the H1-mediated AR triggers.
            2. The **Montelukast** acts as a GINA-approved asthma add-on *and* controls her AR congestion.
            This strategy treats the entire "Unified Airway."</p>`;

            rationaleDiv.innerHTML = rationaleHTML;
            rationaleDiv.style.display = 'block';
        }
    </script>

</body>
</html>